Physician profile
John Turse
NPI 1174505531
$3,034.65
in general payments reported to CMS, 2019-2025
21 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $284 · 2021: $186 · 2022: $119 · 2023: $555 · 2024: $894 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.20 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,617.20 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Phathom Pharmaceuticals, INC. | $216.56 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $195.30 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Braintree Laboratories, INC. | $161.78 | 2019-2024 | Sutab |
| Pfizer INC. | $125.99 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.50 | 2019-2023 | Entyvio, Gattex |
| Celgene Corporation | $100.83 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.07 | 2019-2020 | |
| Ucb, INC. | $69.35 | 2019 | |
| Intercept Pharmaceuticals, INC. | $58.82 | 2019 | |
| Medtronic, INC. | $46.01 | 2021-2024 | Interstim |
| Regeneron Healthcare Solutions, INC. | $44.99 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $41.76 | 2020 | |
| Shire North American Group INC | $37.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2024 | Cyltezo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $23.07 | 2019 | |
| Lilly USA, LLC | $17.17 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $14.97 | 2019 | |
| Evoke Pharma, INC. | $14.45 | 2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $12.87 | 2019 | |
| Phadia US INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Turse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.